Application of radix puerariae EVLPs in preparation of composition for inhibiting ferroptosis of liver cells

Through the extracellular vesicles (EVLPs) extracted from Pueraria root, the ferrodysfunction pathway is suppressed, and the malabsorption and toxicity problems of existing drugs in the treatment of alcoholic liver disease are solved, and the reduction of liver damage indicators such as ALT and AST and iron are achieved. The reversal of death-related indicators significantly improved the liver status of mice with alcoholic liver disease.

CN119074798APending Publication Date: 2024-12-06TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411418195.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-11
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing drugs have malabsorption, poor selectivity and toxicity problems when treating alcoholic liver disease, which is difficult to effectively inhibit iron death in liver cells, resulting in poor treatment effect.

Method used

Extracellular vesicles (EVLPs) extracted from Pueraria root by inhibiting the ferrodynamic pathway, reducing liver damage indicators such as ALT and AST, and increasing the expression of xCT, Nrf2, and p-Nrf2 proteins, and preparing it into oral agents to treat alcoholic liver disease.

Benefits of technology

Pueraria EVLPs significantly reduce liver damage indicators such as ALT and AST, reverse ferrodysfunction related indicators, prolong the residence time in the body, have obvious intervention and protection effects, improve liver steatosis in mice with alcoholic liver disease, reduce ferrodysfunction related indicators, and improve liver antioxidant capacity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074798A_ABST
    Figure CN119074798A_ABST
Patent Text Reader

Abstract

The invention provides application of radix puerariae EVLPs in preparation of a composition for inhibiting ferroptosis of liver cells, and belongs to the technical field of medicines. The radix puerariae EVLPs are extracted from radix puerariae, the particle size is proper, the stability is high, and the in-vivo acting time is long; after the PL-EVLPs are orally taken, the PL-EVLPs can reach the gastrointestinal tract part within 1 hour and gather within 3 hours, and the PL-EVLPs stay longer in the gastrointestinal tract of a disease model compared with a normal body, so that the PL-EVLPs are suitable for oral administration; the PL-EVLPs has an obvious intervention and protection effect on a mouse with the alcoholic liver disease, can improve liver fatty degeneration caused by alcohol and reduce key liver injury index levels such as ALT and AST, and has a reversal effect on ferroptosis related indexes such as Fe < 2 + >, MDA and GSH; the PL-EVLPs can play a role in treating the alcoholic liver disease by inhibiting a ferroptosis pathway.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to the application of Pueraria lobata EVLPs in preparing a composition for inhibiting liver cell ferroptosis. Background Art

[0002] Alcoholic liver disease (ALD) is diffuse liver damage caused by long-term heavy drinking, and is one of the most common causes of morbidity and mortality from liver-related diseases. ALD progresses slowly, with early symptoms of alcoholic liver damage, accompanied by symptoms such as liver cell structural damage, lipid accumulation, and intestinal microbial imbalance. As the disease progresses, it gradually develops into alcoholic fatty liver, hepatitis, and liver fibrosis. In severe cases, it even develops into cirrhosis and hepatocellular carcinoma.

[0003] More and more studies have shown that ferroptosis plays an important role in the pathogenesis of ALD. Long-term drinking can disrupt iron homeostasis, leading to excessive accumulation of iron in the liver, and then inducing ferroptosis. Targeting ferroptosis may be a highly promising intervention strategy for the prevention and treatment of ALD. Ferroptosis is closely related to the occurrence and development of ALD. When the body is overloaded with iron, that is, the accumulation of iron exceeds normal demand, it can damage organs and cause dysfunction, which is a significant feature of ALD. Even mild to moderate drinking can increase the iron content of the liver. Under normal physiological conditions, ROS produced by cells participate in the regulation of signaling pathways, transcription, etc., and excess ROS are cleared or processed by endogenous antioxidant mechanisms to prevent ROS-mediated damage. However, when there is excessive free iron in the body, it accelerates the Fenton reaction, causing cells to produce a large amount of ROS, saturating the endogenous antioxidant mechanism, and then inducing oxidative stress, damaging intracellular proteins, lipids, and macromolecules such as DNA, and seriously interfering with normal cell signal transduction. At the same time, iron-accumulating hepatocytes directly or indirectly (through Kupffer cell activation) secrete pro-inflammatory and pro-fibrotic factors to activate hepatic stellate cells, and persistently activated hepatic stellate cells further promote liver fibrosis, thereby promoting the progression of ALD. Some studies have shown that the liver-protective effects of many compounds on ALD are accompanied by the restoration of iron homeostasis, especially iron chelators and ferroptosis inhibitors, which have been shown to have the potential to prevent ALD. However, the clinical application of such drugs is severely restricted by problems such as poor absorption, poor selectivity, and high toxicity. Therefore, the search for safer and more effective new drugs has become an urgent problem to be solved.

[0004] Plant-derived extracellular vesicles (PDEVs) are nano-sized vesicles extracted from plant extracellular fluid or juice, and are similar to mammalian extracellular vesicles in structure and function. Since PDEVs are derived from natural plants, they have shown many remarkable advantages in the field of disease treatment, such as high biosafety, abundant resources and high yield. More importantly, the independent structure and functional characteristics of PDEVs enable them to be precisely located, which facilitates subsequent monitoring and efficacy evaluation. They perfectly embody the multi-component, multi-target and multi-pathway therapeutic characteristics of the original plants. In addition, PDEVs can not only be used as a whole pharmacological substance in the development of new drugs, but also as a new type of nano-delivery system to accurately target disease organs and exert powerful efficacy. Therefore, PDEVs have great application potential and research value in the field of medicine. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide the use of Pueraria lobata EVLPs in the preparation of a composition for inhibiting liver cell ferroptosis. Pueraria lobata EVLPs reduce the levels of key liver injury indicators such as ALT and AST, and have an effect on the ferroptosis-related indicator Fe 2+ , MDA and GSH all have reversal effects; PL-EVLPs can play a role in treating alcoholic liver disease by inhibiting the ferroptosis pathway.

[0006] In order to achieve the above object, the present invention provides the following technical solutions:

[0007] The present invention provides the use of Pueraria lobata EVLPs in preparing a composition for inhibiting liver cell ferroptosis.

[0008] Preferably, the Pueraria lobata EVLPs can reverse liver cell ferroptosis indicators.

[0009] Preferably, the Pueraria lobata EVLPs can inhibit the ferroptosis pathway of liver cells.

[0010] Preferably, the Pueraria lobata EVLPs can increase the expression levels of xCT protein, Nrf2 protein, and p-Nrf2 protein.

[0011] Preferably, the Pueraria lobata EVLPs can be prepared as an oral dosage form.

[0012] Preferably, the Pueraria lobata EVLPs can be used to prepare drugs for treating alcoholic liver disease.

[0013] Preferably, the particle size of the Pueraria lobata EVLPs is 120 to 130 nm, and the Zeta potential is -45 to -55 mV.

[0014] Contains at least the following beneficial technical effects:

[0015] The present invention extracts Pueraria lobata EVLPs from Pueraria lobata, which have a more suitable particle size and higher stability, and have a long duration of action in the body; after oral administration of PL-EVLPs, they can reach the gastrointestinal tract in 1 hour and aggregate in 3 hours. Compared with the normal body, PL-EVLPs stay in the gastrointestinal tract of the disease model for a longer time, and are suitable for oral administration; PL-EVLPs have a significant intervention and protective effect on mice with alcoholic liver disease, can improve liver fatty degeneration caused by alcohol, reduce the levels of key liver injury indicators such as ALT and AST, and have an effect on the iron death-related indicator Fe 2+ , MDA and GSH all have reversal effects; PL-EVLPs can play a role in treating alcoholic liver disease by inhibiting the ferroptosis pathway. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 Transmission electron microscopy image of PL-EVLPs (scale bar = 500 nm).

[0017] Figure 2 Figure 2 shows the particle size of PL-EVLPs.

[0018] Figure 3 This is the potential diagram of PL-EVLPs.

[0019] Figure 4 The graph shows the particle size changes of PL-EVLPs at different pH values.

[0020] Figure 5 The distribution of PL-EVLPs in normal mice and model group mice.

[0021] Figure 6 The distribution of PL-EVLPs in cells at different time points.

[0022] Figure 7 This is the co-localization curve of PL-EVLPs and cell nucleus.

[0023] Figure 8 The cytotoxicity test of different concentrations of PLEVLPs.

[0024] Fig. 9 The cytotoxicity test of ethanol at different volume fractions.

[0025] Fig.10 The uptake of PL-EVLPs by HepG2 cells at different time points.

[0026] Fig.11 The effect of different concentrations of PL-EVLPs on ethanol-induced cell survival rate.

[0027] Fig.12The effects of PL-EVLPs on ethanol-induced cell-related indicators.

[0028] Fig.13 Effects of PL-EVLPs on ROS levels in HepG2 cells induced by ethanol.

[0029] Fig.14 This is a liver pathological section.

[0030] Fig.15 This is the survival curve of mice after HP-Res / Cur administration.

[0031] Fig.16 The effects of PL-EVLPs on liver tissue related indicators.

[0032] Fig.17 Western blot results and statistical graphs. DETAILED DESCRIPTION

[0033] The technical solution of the present invention is further described below through the accompanying drawings and embodiments.

[0034] Unless otherwise defined, technical or scientific terms used in the present invention shall have the common meanings understood by one having ordinary skills in the field to which the present invention belongs.

[0035] It is obvious to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the present invention can be implemented in other specific forms without departing from the main idea or essential features of the present invention. Therefore, from all points of view, the embodiments should be regarded as exemplary and non-restrictive, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention, and any reference numerals in the claims should not be regarded as limiting the claims involved.

[0036] In addition, it should be understood that although this specification is described according to the implementation modes, not every implementation mode includes only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment can also be appropriately combined to form other implementation modes that can be understood by those skilled in the art. These other implementation modes are also covered within the protection scope of the present invention.

[0037] It should also be understood that the specific embodiments described above are only used to explain the present invention, and the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field, within the technical scope disclosed by the present invention, can make equivalent replacements or changes based on the technical solutions and inventive concepts of the present invention, which should be covered by the protection scope of the present invention / invention.

[0038] Example 1

[0039] Extraction of PL-EVLPs

[0040] Weigh 250g of fresh kudzu root, wash and cut into small pieces of about 1cm, add 500mL of 1×PBS solution, put it into a juicer to squeeze the juice, squeeze the juice for a total of 5min, stop for 10s every 30s, and get fresh kudzu root juice. Filter the juice through 6 layers of filter cloth to remove the debris in the juice, centrifuge at 4000g, 4℃ for 30min to remove cell debris, take the supernatant and continue to centrifuge at 12000g, 1h to remove fibers and large vesicles. Finally, centrifuge the supernatant at 110000g, 4℃ for 2h, discard the supernatant, and gently blow the bottom precipitate with an appropriate amount of 1×PBS phosphate buffer, vortex for 3min to resuspend the precipitate, and obtain the crude PL-EVLPs extract.

[0041] 1. Purification of PL-EVLPs

[0042] Sucrose density gradient centrifugation was used to further purify the crude PL-EVLPs extract. 8%, 30%, 45% and 60% sucrose solutions were prepared respectively and centrifuged at 110000g and 4°C for 2h. Then, a layer of solution where PL-EVLPs aggregated was drawn, and an appropriate amount of PBS solution was added to wash once under the same centrifugation conditions. Finally, the precipitate was resuspended in PBS solution to obtain purified PL-EVLPs.

[0043] 2. Morphological Characterization of PL-EVLPs

[0044] Tungsten filament transmission electron microscopy (TEM) was used to observe the morphology of PL-EVLPs: First, the sealing film was spread flat on a glass slide, and a copper mesh was placed on the sealing film; then an appropriate amount of PL-EVLPs stock solution was dropped on the copper mesh and left to stand for about 10 minutes, and then 10 μL of 3% uranyl acetate was added for staining for 1-3 minutes, and the copper mesh was dried naturally. TEM was used to take pictures and observe the morphology of PL-EVLPs, see Figure 1 .

[0045] PL-EVLPs have a distinct double-layer membrane structure and present a classic saucer-like or concave spherical shape.

[0046] 3. Particle size and potential measurement of PL-EVLPs

[0047] Take an appropriate amount of PL-EVLPs, add 1×PBS solution to dilute to an appropriate concentration, draw 1mL of PL-EVLPs dilution into the sample pool, and put it into the instrument. Use malvern nanoZEN3600 in automatic mode to measure the particle size, polydispersity coefficient and zeta potential of PL-EVLPs at room temperature. Figure 2 , Figure 3 .

[0048] The particle size and potential of PL-EVLPs were measured by Malvern particle size / potential meter. The particle size distribution of PL-EVLPs is uniform, with a good PDI value of 0.126, and its size range is between 125±5nm. The Zeta potential results show that PL-EVLPs are stable and its Zeta potential is negative, between -45 and -55mV, indicating that the surface of PL-EVLPs has a negative charge layer.

[0049] 4. Stability of PL-EVLPs

[0050] Prepare pH = 1.2 gastric fluid simulation solution, pH = 7.4 small intestine simulation solution and pH = 6.8 colon simulation solution, add PL-EVLPs to each simulation solution in appropriate proportions for dilution, incubate with the simulation solution for 30 minutes, and then place in the malvernnanoZEN3600 instrument to detect changes in particle size and polydispersity coefficient. (Gastric fluid simulation solution: pH = 1.2 HCl, 0.01 g / mL pepsin; small intestine simulation solution: 20% 0.1 mol / L potassium dihydrogen phosphate solution, 80% 0.1 mol / L potassium dihydrogen phosphate solution, 2% pancreatic enzyme solution; intestinal simulation solution 50% 0.1 mol / L potassium dihydrogen phosphate solution, 50% 0.1 mol / L potassium dihydrogen phosphate solution), see Figure 4 .

[0051] Since oral drugs experience harsh conditions during transportation and absorption through the gastrointestinal tract, such as gastric acid and a gastric environment rich in digestive enzymes, the stability of PL-EVLPs under different pH conditions was tested. The results showed that after 30 minutes of incubation in pH = 1.2 gastric fluid simulation, pH = 6.8 colon simulation, and pH = 7.4 small intestine simulation, the particle size of PL-EVLPs increased to a certain extent compared with that in PBS, but the particle size remained below 200nm.

[0052] Experimental Example 2

[0053] Studies have shown that PDEVs can be eaten directly and absorbed through the gastrointestinal tract to play a cross-border regulatory role. PDEVs are administered through different routes and their biodistribution is also different. For example, intraperitoneal injection is generally distributed in the liver, spleen, and kidneys, nasal administration is mainly distributed in the lungs and brain, intramuscular injection is distributed in the muscles, and oral administration is distributed in the gastrointestinal tract. The key to the efficacy of PL-EVLPs lies in whether they can be effectively ingested and reach the lesion site. Therefore, this chapter mainly explores whether PL-EVLPs can be absorbed into the blood after oral administration, and whether they can be ingested by cells to play a role.

[0054] 1. Fluorescent labeling of PL-EVLPs

[0055] Preparation of dye working solution: Dilute DiR fluorescent dye 10 times with 1×PBS solution to prepare a dye working solution with a concentration of 100μM. PL-EVLPs staining: Add dye working solution to PL-EVLPs suspension, add 100μL dye working solution to every 1000μL PL-EVLPs suspension. Then mix on a vortex oscillator for 1min and incubate at 37°C for 30min; add an appropriate amount of 1×PBS to the incubated PL-EVLPs dye complex and mix well, extract again according to the PL-EVLPs extraction method to remove excess dye, and finally take 200μL 1×PBS to resuspend the precipitate. The precipitate is the stained PL-EVLPs.

[0056] 2. In vivo imaging analysis of PL-EVLPs

[0057] In order to monitor the biodistribution of PL-EVLPs in mice, mice from the control group and the alcoholic liver disease model group were randomly selected, and each mouse was gavaged with 200 μL DiR-labeled PL-EVLPs. The mice were anesthetized at 1 h, 3 h, and 6 h, respectively, and observed and photographed using the small animal in vivo optical imaging system.

[0058] See Figure 5 , normal mice and alcoholic liver disease model mice orally administered DiR-labeled PL-EVLPs for 1h, 3h, and 6h, fluorescence aggregation can be seen in the gastrointestinal tract. In normal mice, PL-EVLPs almost reached the peak absorption at 3h. Although fluorescence distribution was still observed in the gastrointestinal tract at 6h, it dissipated to a certain extent, and it was speculated that part of the PL-EVLPs was metabolized. In the model group mice, obvious fluorescence aggregation was still observed in the gastrointestinal tract 6h after oral administration of PL-EVLPs, indicating that the prolonged residence time of PL-EVLPs in the model group mice had a certain effect on the diseased mice.

[0059] 3. Cellular Localization Analysis of PL-EVLPs

[0060] PKH67 fluorescent labeling: Take 1 μL PKH67 dye, add 9 μL diluent to dilute 10 times to obtain PKH67 mother solution, then add 1× PBS solution to dilute the mother solution 25 times to obtain the final staining solution. Add 1 mL PL-EVLPs to the prepared PKH67 staining solution, mix well, incubate at 37°C for 5 minutes, and then incubate at 4°C for 15 minutes. Add the incubated vesicle solution to the inner tube of the ultrafiltration tube, put it in a centrifuge, centrifuge at 4000g, 4°C for 10 minutes, and after centrifugation, resuspend the PL-EVLPs in the inner tube with a certain volume of 1× PBS solution until complete, collect it in a centrifuge tube and store it at -20°C away from light.

[0061] Cell slides, fixation and sealing: HepG2 cells were plated at an appropriate density in a 24-well plate containing cell slides. After incubation in an incubator for 24 hours, the old culture medium was discarded, and serum-free culture medium containing PKH67-labeled PL-EVLPs was added. After co-incubation for 1, 3, and 6 hours, the cells were washed twice with PBS to remove excess drugs and fixed in a paraformaldehyde solution for 20 minutes. The cell nuclei were stained with DAPI. Cell uptake was observed and photographed under an upright fluorescence microscope.

[0062] When cells were co-incubated with fluorescently labeled PL-EVLPs for different periods of time, the fluorescence of PL-EVLPs could be obtained near the cell nucleus, and as the incubation time increased, the number of PL-EVLPs engulfed by the cells also increased. The colocalization curve results showed that after PL-EVLPs and the cell nucleus were engulfed by the cells, they were distributed in the cytoplasm near the cell nucleus.

[0063] Animal live imaging and fluorescence microscopy techniques were used to explore the distribution of PL-EVLPs in the body or cells after ingestion. After oral administration of PL-EVLPs, they can reach the gastrointestinal tract at 1 hour and accumulate in large quantities at 3 hours. Compared with the normal body, PL-EVLPs stay in the gastrointestinal tract of the disease model longer. At the cellular level, when HepG2 cells were incubated with fluorescently labeled PL-EVLPs for different time points (1, 3, and 6 hours), PL-EVLPs aggregated to varying degrees near the cell nucleus, and at 6 hours, PL-EVLPs were basically taken up by cells; further study of its localization in organelles found that PL-EVLPs could reach the vicinity of lysosomes after incubation with HepG2 cells for 12 hours.

[0064] Example 3

[0065] 1. After alcohol intake, it usually needs to be metabolized, processed, and transformed by the liver before being excreted from the body, making the liver particularly vulnerable to damage and invasion by alcohol metabolites. Alcoholic liver disease is the pathological basis of a variety of chronic liver diseases. If not intervened in time, it will lead to fatty degeneration and inflammation of liver cells, and later develop into liver fibrosis, and even develop into cirrhosis and hepatocellular carcinoma in severe cases. At present, the intrinsic pathogenic mechanism of alcoholic liver disease has not been systematically explained, resulting in a lack of specific drugs for the treatment of the disease in clinical practice. Therefore, it is very important to clarify the molecular mechanism of alcoholic liver disease and find effective drugs to treat the disease. In this study, an ethanol-stimulated HepG2 cell model was established in vitro and an alcoholic liver disease mouse model was established in vivo. The intervention and protective effects of PL-EVLPs on alcoholic liver disease were jointly analyzed through cell experiments and animal experiments, laying the foundation for the early prevention of alcoholic liver disease.

[0066] 1.1 Cell culture

[0067] Cell recovery: Carefully remove the frozen cells from the -80℃ refrigerator and dissolve them in a 37℃ water bath. Then add the cell suspension to a centrifuge tube containing 3mL of complete culture medium. Set the centrifugation parameters to 1000rpm for 5min to remove DMSO from the cryopreservation solution. Add an appropriate amount of complete culture medium to the cell suspension precipitate after centrifugation, gently pipet 50 times to mix, and place in a T25 culture flask for culture. Observe the cells in time at the early stage of recovery and change the medium in time.

[0068] Cell passaging: Observe the cell state under a microscope and digest it in time when it grows to 80-90%. Use a pipette to remove the old culture medium, rinse twice with 2mL pH 7.4 PBS, add 1mL trypsin digestion solution, incubate in a 37℃ incubator for 1min, take out, tap the culture bottle gently to make the cells fall off, then add 3mL complete culture medium, pipette into a centrifuge tube, 1000rpm, 5min. Resuspend the precipitate with complete culture medium and transfer to a new culture bottle for culture at a ratio of one to two. Formal experiments begin after three generations.

[0069] Cell cryopreservation: Obtain cell suspension according to the cell passage method. Prepare cryopreservation solution by mixing fetal bovine serum and DMSO in a volume ratio of 9:1 and add it to a centrifuge tube. Use a pipette to gently blow to resuspend the cells and transfer them to cryopreservation tubes. Use a marker to mark the cell name, name of the cryopreservant, cryopreservation time and generation number. Finally, seal the cryopreservation tube with sealing film and carefully store it in a -80℃ refrigerator.

[0070] 1.2 Cytotoxicity MTT assay

[0071] To detect the toxicity of PL-EVLPs to HepG2 cells. HepG2 cells were cultured at 8×10 4 The cells were plated at a density of 100 μL / mL in a 96-well plate. After incubation in the incubator for 24 hours, the old culture medium was discarded, and serum-free culture medium containing different concentrations of PL-EVLPs was added and incubated for another 24 hours. The drug-containing culture medium was aspirated, 100 μL of 5% MTT solution was added, and after incubation for 4 hours, MTT was discarded, 150 μL of DMSO solution was added to each well, and then the absorbance of each well was detected at 490 nm.

[0072] 1.3 Quantitative cell uptake

[0073] HepG2 cells were cultured at 6×10 5 The cells were seeded at a density of 100 cells / mL in a 6-well plate. After the cells adhered to the wall, the old culture medium was discarded and the cells were incubated with PKH67-labeled drug-containing culture medium for different time periods (1, 3 and 6 h). The cells were washed with PBS and digested with trypsin, and then the cells were collected. The uptake efficiency of PL-EVLPs by cells at different times was quantitatively detected by flow cytometry.

[0074] 1.4 In vitro experiments on alcoholic liver disease Establishment of in vitro model of alcoholic liver disease

[0075] HepG2 cells were cultured at 8×10 4 The cells were inoculated at a density of 100 μL / mL in a 96-well plate and incubated in an incubator for 24 h. The old culture medium was discarded and serum-free culture medium containing different volume fractions of ethanol (1, 2, 3, 4, 5, 6, 7 and 8%) was added. After further incubation for 24 h, the ethanol-containing culture medium was aspirated and 100 μL of 5% MTT solution was added. After incubation for 4 h, the MTT was discarded and 150 μL of DMSO solution was added to each well. The absorbance of each well was then detected at 490 nm.

[0076] Effect of PL-EVLPs intervention on the survival rate of ethanol-induced HepG2 cells: According to the results of the in vitro model, the optimal volume fraction of ethanol for modeling was 3.5%. 4 The cells were inoculated at a density of 100 / mL in a 96-well plate and incubated in an incubator for 24 hours. After the cells adhered to the wall, the old culture medium was discarded. The blank group, control group and drug-containing group were added with serum-free culture medium, serum-free culture medium containing 3.5% ethanol and serum-free culture medium containing different drug concentrations, respectively. After incubation for 4 hours, the culture medium was removed and serum-free culture medium containing 3.5% ethanol was added to continue incubation until the next day. Then the MTT experiment was performed to detect the cell survival rate.

[0077] 1.5 Total RNA extraction from PL-EVLPs

[0078] RNA was extracted from PL-EVLPs according to the total RNA extraction method of blood samples in the kit (TransZolUp Plus RNA Kit), and the RNA concentration was detected using Nano drop.

[0079] 1.6 Cellular ROS detection

[0080] ① Cell plating and drug administration After HepG2 cells were digested and counted, 2.8×10 5 The cells were plated at a density of 100 cells / mL in a 24-well plate. After the cells adhered to the wall, the drugs were administered respectively (specific groups are shown in the table below). 5 hours after the drug administration, except for the positive control group, the other groups were replaced with alcohol-containing culture medium and incubated until the next day. The positive group was replaced with complete culture medium, see Table 1.

[0081] Table 1

[0082]

[0083] ② Loading probe and imaging DCFH-DA was diluted with serum-free culture medium at a ratio of 1:1000 to a final concentration of 10 μmol / L. The cell culture medium was removed, 500 μL of the diluted DCFH-DA was added, and the cells were incubated in a 37°C cell culture incubator for 20 min. The cells were washed three times with serum-free cell culture medium, and finally, an appropriate amount of PBS was added to each well and photographed and recorded under a fully automatic intelligent fluorescence imaging instrument (EVOSM7000).

[0084] 1.7 Cellular Fe 2+ , MDA and GSH content detection

[0085] ① Cell plating and drug administration HepG2 cells were digested and counted according to 2×10 6 After the cells adhered to the wall, the drugs were administered according to the normal group, model group, PL-EVLPs group, RNA group and Fer-1 group. After 5 hours of administration, except for the normal group, the complete medium was continued to be administered, and the complete medium containing 3.5% alcohol was replaced in the other groups until the cells were collected the next day.

[0086] ② Collect and lyse cells. Add 1 mL of trypsin to each culture bottle. Digest in the incubator for about 1 to 2 minutes, then add culture medium to terminate digestion. Pipette cells into the culture medium, collect into a 15 mL centrifuge tube, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, wash twice with PBS, add 100 μL of cell lysis solution and 1 μL of protease inhibitor, place on ice for lysis, pipette once every 10 minutes. Centrifuge at 11000 rpm for 10 minutes.

[0087] ③ Protein quantification: Take the cell supernatant for BCA protein quantification.

[0088] ④ The indicators were determined and tested according to the instructions of each kit.

[0089] 1.8 Establishment of the mouse model of alcoholic liver disease

[0090] Twenty-four male C57B / 6J mice (8 weeks old, 18-20g) were placed under standard experimental conditions: 12h day and night alternation, ambient temperature of 24±2℃, and ambient humidity of 35±5%. After 3 days of adaptive feeding (ordinary solid feed, water and food ad libitum), they were randomly divided into control group, model group, PL-EVLPs low-dose group, and high-dose group. Subsequently, different feeds were given for 1 week of adaptation, the control group was given Lieber DeCarli control liquid feed (free diet, no water provided), and the model and drug-treated groups were given Lieber DeCarli alcohol liquid feed (free diet, no water provided). The ethanol concentration was gradually increased from 1% to 5% during this week. In the next 10 days, mice in the low- and high-dose groups were gavaged with PL-EVLPs (at a concentration of 4mg / kg and 16mg / kg) every day, and the control group and model group were given PBS every day. After the last administration, the mice were fasted. At 7-9 am the next day, the mice in the model group and the treatment group were gavaged with 31.5% alcohol solution; the mice in the control group were gavaged with 45% maltodextrin solution. After fasting and water deprivation for 9 hours, the mice were killed by removing their eyeballs and drawing blood, and the serum was separated and the liver tissue was taken, as shown in Table 2.

[0091] Table 2

[0092]

[0093] 1.9 Histopathological analysis

[0094] HE staining was used to observe the morphological changes of mouse liver tissue caused by PL-EVLPs. HE staining process: paraffin sections were dewaxed with xylene, hydrated, stained with hematoxylin for 10 minutes, differentiated, stained with eosin, dehydrated, transparentized with xylene, and sealed with neutral resin glue. The liver lesions of mice were observed under HE staining, and the liver pathological sections were evaluated.

[0095] 1.10 Serum ALT, AST and Fe 2+ Content analysis

[0096] After the mouse eyeballs were removed and blood was collected, the serum was placed in a 4°C refrigerator overnight, then centrifuged at 3500 rpm for 10 minutes, the supernatant was carefully aspirated into a clean centrifuge tube, and then centrifuged at 3000 rpm for 10 minutes. The supernatant was aspirated for ALT, AST and Fe 2+ Carry out the corresponding determination according to the instructions of the kit.

[0097] 1.11 Tissue MDA, GSH and Fe 2+ Detection

[0098] ① Tissue pretreatment For the determination of MDA and GSH, first accurately weigh the liver tissue, add 9 volumes of physiological saline at a ratio of weight (g): volume (mL) = 1:9, chop the tissue, prepare homogenate in an ice water bath, centrifuge at 3000rpm for 10 minutes, and take the supernatant, i.e. 10% homogenate supernatant, for determination of Fe 2+ , weigh 0.1g tissue, add 1mL reagent 1 for ice bath homogenization, then centrifuge at 10000g, 4℃ for 10min, take the supernatant and place it on ice for testing. At the same time, use the BCA kit to determine the protein concentration of the prepared sample for calculation.

[0099] ②Indicator determination was carried out according to the instructions of the corresponding test kit.

[0100] 2. Experimental results

[0101] 2.1 MTT toxicity assay of PL-EVLPs and ethanol on cells

[0102] In order to study the in vitro compatibility of PL-EVLPs and the appropriate concentration for in vitro injury model, MTT experiments were performed on cells with different concentrations of PL-EVLPs and different volume fractions of ethanol.

[0103] like Figure 8-9 As shown in the figure, within a certain concentration range, PL-EVLPs were co-incubated with HepG2 cells for 24 hours, and there was no obvious toxic effect on cell survival rate, and there was a certain promoting effect on cell proliferation. When the concentration of PL-EVLPs was 600 μg / mL, there was no significant difference in cell survival rate from that of the normal group. At the same time, the cells were co-incubated with different volume fractions of ethanol for 24 hours, and the volume fraction at ICso was screened. The results showed that when the volume fraction of ethanol was 3.5%, the cell survival rate was 50%, so 3.5% ethanol was selected as the modeling concentration of the in vitro model.

[0104] 2.2 Determination of cellular uptake efficiency

[0105] The key to the efficacy of drugs in cells lies in the uptake of drugs by cells. In order to explore whether cells can effectively internalize drugs, flow cytometry was used to quantitatively detect cells after incubation with fluorescently labeled PL-EVLPs for different periods of time.

[0106] It was found that the average fluorescence signal detected gradually increased with the increase of time, indicating that PL-EVLPs were effectively engulfed by HepG2 cells with the increase of time. Fig.10 .

[0107] 2.3 Evaluation of the efficacy of PL-EVLPs on ethanol-induced cells

[0108] In order to explore the in vitro intervention effect of PL-EVLPs on ethanol-induced HepG2 cells, ethanol was used to induce cells after intervention with different concentrations of PL-EVLPs. Fig.11 Compared with no drug intervention, the cell survival rate increased after pre-intervention with different concentrations of PL-EVLPs, and there was no significant difference between the cell survival rate and the normal group after intervention with 600μg / mL PL-EVLPs. This shows that different concentrations of PL-EVLPs can play a pre-protective role against liver cell damage caused by ethanol, and in this concentration range, 600μg / mL is the best concentration, so this concentration was selected as the concentration used in subsequent experiments.

[0109] 2.4 Effect of PL-EVLPs on ethanol-induced cell Fe 2+ , GSH, MDA and ROS indicators

[0110] Ethanol can lead to abnormal accumulation of cellular iron ions, causing excessive production of ROS and lipid peroxidation damage. Ferrostatin-1 (Fer-1) is a synthetic compound that can effectively inhibit ferroptosis. Figure 12-13 As shown in the figure, compared with the control group, HepG2 cells after ethanol treatment gradually produced and accumulated a large amount of iron ions, MDA and ROS, while the GSH level decreased. The abnormal accumulation of iron ions, excessive production of ROS and lipid peroxidation damage were significantly alleviated after the cells were pre-incubated with PL-EVLPs and Fer-1, respectively. In addition, the RNA component in PL-EVLPs had no significant effect on the GSH level, but it had a reversal effect on the cell damage indicators caused by ethanol to a certain extent.

[0111] 2.5 Liver tissue and pathological analysis

[0112] HE staining was used to observe the distribution and morphology of mouse liver tissue cells. Fig.14 As shown in the figure, the hepatocytes in the blank control group (Control) were normal in morphology, with similar nuclei, neatly arranged liver plates in radial shape, and no swelling or inflammatory infiltration of the hepatocytes. In the model group (Model), the hepatocytes were disorderly arranged, the liver cords were unclear, and there was a large amount of fat vacuoles accumulated and inflammatory cell infiltration. In the low-dose group (Low-PL-EVLPs), the liver tissue structure was relatively clear and the cell morphology was good; but slight fat vacuoles also appeared. In the high-dose group (High-PL-EVLPs), the fatty degeneration was significantly improved, there were basically no fat vacuoles, and the liver tissue structure was more similar to the blank group.

[0113] 2.6 Serum ALT, AST and Fe in PL-EVLPs mice 2+ The influence of content

[0114] Serum ALT and AST levels are considered key biochemical indicators for evaluating the degree of liver damage. Fig.15 As shown in the figure, the serum ALT and AST of the mice in the model group were significantly increased compared with the blank group (p<0.001), and the ALT and AST levels of each drug-treated group were significantly decreased compared with the model group (p<0.05), and the decrease level in the high-dose drug-treated group was more obvious than that in the low-dose drug-treated group, indicating that PL-EVLPs has a certain effect on improving liver cell damage and can play a liver-protecting role as a Chinese medicine. Alcohol can interfere with normal iron metabolism, leading to excessive deposition of iron in the liver, which in turn causes liver damage, resulting in decreased serum iron. Compared with the control group, the serum iron content in the model group decreased significantly, and its level was adjusted after PL-EVLPs intervention.

[0115] Effects of PL-EVLPs on MDA, GSH and Iron Content in Mouse Liver Tissue

[0116] like Fig.16 As shown in the figure, compared with the control group, the levels of MDA and iron ions in the liver tissue of the mice in the model group were significantly increased, while the level of GSH was significantly lower than that in the control group. All indicators in the liver tissue of the mice in the PL-EVLPs intervention group were reversed, and the content of MDA and iron ions was adjusted back to no significant difference with the control group, and the level of GSH was increased to a certain extent compared with the control group.

[0117] Through in vitro and in vivo efficacy experiments, it was verified that PL-EVLPs has an intervention and protective effect on alcoholic liver disease, and the inhibitory effect of PL-EVLPs on ferroptosis was preliminarily explored. The experiment found that PL-EVLPs can alleviate the damage of ethanol to HepG2 cells and has an effect on MDA and Fe 2+ At the same time, PL-EVLPs has a significant intervention and protective effect on mice with alcoholic liver disease, improving liver fatty degeneration caused by alcohol, reducing the levels of key liver injury indicators such as ALT and AST, and reducing the level of iron death-related indicators Fe 2+ , MDA and GSH all have a reversing effect.

[0118] Example 4

[0119] Effects of PL-EVLPs on protein expression in liver tissue of mice with alcoholic liver disease

[0120] WB results are as follows Fig.17Compared with the control group, the xCT protein content in the liver tissue of the model group mice was significantly reduced. After PL-EVLPs treatment, the xCT protein expression increased significantly and increased in a dose-dependent manner. Compared with the model group, the low-dose xCT protein expression was significantly different, and the high-dose group xCT protein expression was extremely significantly different. After PL-EVLPs intervention, the expression of Nrf2 and p-Nrf2 proteins in the liver tissue of mice was adjusted back, and the difference was significant compared with the protein expression of the model group (p<0.05).

[0121] The experiment found that PL-EVLPs can increase the protein expression levels of Nrf2, p-Nrf2 and xCT, indicating that PL-EVLPs may play a role in treating alcoholic liver disease by inhibiting the ferroptosis pathway.

[0122] The above description is only the preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. Application of Pueraria lobata EVLPs in the preparation of a composition for inhibiting liver cell ferroptosis.

2. The use according to claim 1, characterized in that: The Pueraria lobata EVLPs can reverse the ferroptosis indicators of liver cells.

3. The use according to claim 1, characterized in that: The Pueraria lobata EVLPs can inhibit the ferroptosis pathway of liver cells.

4. The use according to claim 1, characterized in that: The Pueraria lobata EVLPs can increase the expression levels of xCT protein, Nrf2 protein, and p-Nrf2 protein.

5. The use according to claim 1, characterized in that: The Pueraria lobata EVLPs can be prepared into an oral dosage form.

6. The use according to claim 1, characterized in that: The Pueraria lobata EVLPs can be used to prepare medicines for treating alcoholic liver disease.

7. The use according to claim 1, characterized in that: The particle size of the Pueraria lobata EVLPs is 120 to 130 nm, and the Zeta potential is -45 to -55 mV.